

## Acknowledgements

We are grateful to Genethon for providing us with retroviral supernatants through the Therapeuskin consortium, to Dagmar Wirth for the Flp293A-E1aColVII1 producer clone and to Alain Hovnanian for stimulating discussions. We are also grateful to Steeve Vermot and Jeanne Vannod for excellent technical help, to Patrick Reichenbach and Giulietta Maruggi for the help in Southern blotting, to Matthias Titeux for sharing his grafting protocol and to Stéphanie Rosset for technical assistance with TEM. We also thank Olivier Dormond for pRb, p21, Ras and GAPDH antibodies, Alessandro Amici for help with the tumorigenic assay and critical reading of the manuscript, Jean-Daniel Tissot for supplying us with human plasma, Alvaro Baptista and the Department of Pathology at the CHUV with skin samples and Rainer Follador from Microsynth for helpful discussion. We are particularly grateful to continuing support from La Fondation Enfants Papillons and Dr Elisabeth Gianadda, DEBRA-CH and the patient's family. YB was supported by the EPFL, the CHUV and the European Commission through the 6th (Therapeuskin) and 7<sup>th</sup> (Opti-Stem) framework programmes. FM was supported by the Italian Ministry of Health, the Progetto Malattie Rare (RF-EMR-2008-1210900) and the European Research Council (ERC-2010-AdG, GT-Skin).

## Author contributions

SD-GL performed the experiments, organised the collaborative work and inter-

Bianco P, Barker R, Brus  
Goldstein L, Lindvall  
therapies under att  
1489–1495

Bianco P, Cao X, Frenet  
(2013b) The meaning  
science of mesenchy

Biffi A, Montini E, Lorio  
S, Calabria A, Canale  
therapy benefits met

Bonfanti P, Claudinot S,  
(2010) Microenviron  
skin multipotent ste

Bruckner-Tuderman L, H  
anchoring fibrils: les  
*Biol* 18: 43–54

Buchholz CJ, Sanzenbac  
exemption clause-ne

Cartier N, Hacein-Bey-A  
Kutschera I, Vidaud M  
Hematopoietic stem  
adrenoleukodystroph



Published online: February 27, 2015

## Research Article



EMBO  
Molecular Medicine

# A single epidermal stem cell strategy for safe *ex vivo* gene therapy

Stéphanie Droz-Georget Lathion<sup>1,2</sup>, Ariane Rochat<sup>1,2</sup>, Graham Knott<sup>3</sup>, Alessandra Recchia<sup>4</sup>, Danielle Martinet<sup>5</sup>, Sara Benmohammed<sup>6</sup>, Nicolas Grasset<sup>1,2</sup>, Andrea Zaffalon<sup>1,2</sup>, Nathalie Besuchet Schmutz<sup>5</sup>, Emmanuelle Savioz-Dayer<sup>1,2</sup>, Jacques Samuel Beckmann<sup>5,6</sup>, Jacques Rougemont<sup>7</sup>, Fulvio Mavilio<sup>4,8</sup> & Yann Barrandon<sup>1,2,\*</sup>

## Abstract

There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for *ex vivo* autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corrected stem cells before they are transplanted. To address this, we have developed a strategy for the generation of a clonal population of geneti-

**Keywords** cell therapy; regulatory affairs; stem cells; wound healing

**Subject Categories** Regenerative Medicine; Stem Cells; Skin

**DOI** 10.15252/emmm.201404353 | Received 18 June 2014 | Revised 8 January 2015 | Accepted 21 January 2015

## Introduction